Internal Medicine, Hematology · New York, NY
NPI
1053552943
Since 2009
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
622 W 168th St
New York, NY, 10032
Phone (212) 305-0566
Groups this clinician bills Medicare through
Medicare paid, 2024
$40K
432 services
Medicare patients, 2024
58
Average age 76
Drug cost, 2024
$3.2M
493 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Todd L Rosenblat was code 99233 (hospital e&m - subsequent), 198 times for 29 patients. In total Todd L Rosenblat billed 432 services in 12 codes, and Medicare paid $40K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-02-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 198 | 29 | $102.99 | $20K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 94 | 27 | $13.50 | $1,269 |
| 99215 Office E&M - Established | Office | 83 | 24 | $143.51 | $12K |
| 99223 Hospital E&M - Initial | Facility | 16 | 12 | $150.36 | $2,406 |
By year: 2022 $41K for 424 services; 2023 $44K for 381 services; 2024 $40K for 432 services.
Medicare prescription drug claims, 2024
In 2024, the drug Todd L Rosenblat prescribed most often to Medicare patients was Hydroxyurea, with 85 prescriptions and refills. In total Todd L Rosenblat wrote 493 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 85 | 146 | 14 | $1,788 |
| Imatinib Mesylate Generic | 71 | 71 | Under 11 | $44K |
| Sprycel Dasatinib | 58 | 64 | Under 11 | $996K |
| Scemblix Asciminib Hydrochloride | 34 | 34 | Under 11 | $700K |
| Jakafi Ruxolitinib Phosphate | 31 | 37 | Under 11 | $622K |
| Valacyclovir Valacyclovir Hcl | 29 | 39 | Under 11 | $1,160 |
| Allopurinol Generic | 27 | 48 | Under 11 | $252 |
| Imbruvica Ibrutinib | 13 | 13 | Under 11 | $203K |
| Calquence Acalabrutinib Maleate | 13 | 13 | Under 11 | $186K |
| Xarelto Rivaroxaban | 12 | 12 | Under 11 | $7,874 |
| Eliquis Apixaban | 11 | 11 | Under 11 | $6,176 |
Brand drugs: - claims; generic drugs: 293 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Todd L Rosenblat were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.